Valuation: Asymchem Laboratories (Tianjin) Co., Ltd.

Market Cap 54.6B 8.12B 6.96B 6.51B 5.95B 11.23B 778B 11.35B 77.05B 29.96B 391B 30.49B 29.83B 1,292B P/E 2026 *
41.8x
P/E 2027 * 31.9x
Enterprise Value 50.22B 7.47B 6.4B 5.99B 5.47B 10.33B 715B 10.44B 70.86B 27.55B 359B 28.04B 27.44B 1,188B EV / Sales 2026 *
6.22x
EV / Sales 2027 * 5.23x
Free-Float
61.13%
Yield 2026 *
0.81%
Yield 2027 * 1.15%
Manager TitleAgeSince
Chief Executive Officer 70 1998-10-06
Chief Executive Officer 49 2022-01-18
President - -
Director TitleAgeSince
Director/Board Member 49 2011-07-17
Chairman 70 1998-10-06
Director/Board Member 65 2011-07-17
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 8.12B
-0.35%+5.39%+75.21%+127.54% 1,111B
-0.54%+4.07%+52.29%+65.39% 658B
-0.16%+5.67%+25.60%+80.40% 467B
+0.23%+2.66%+42.55%+42.94% 369B
+0.25%+1.05%+25.33%+41.42% 301B
+1.04%+3.39%+2.81%+14.50% 256B
-0.34%+5.83%+51.11%+72.96% 240B
+2.47%+3.22%-16.72%-52.13% 207B
-0.04%+5.63%+27.86%+92.24% 182B
Average +0.23%+4.49%+31.78%+53.92% 421.22B
Weighted average by Cap. -0.01%+4.68%+44.28%+73.30%

Financials

2026 *2027 *
Net sales 8.07B 1.2B 1.03B 962M 880M 1.66B 115B 1.68B 11.39B 4.43B 57.72B 4.51B 4.41B 191B 9.72B 1.45B 1.24B 1.16B 1.06B 2B 138B 2.02B 13.72B 5.33B 69.52B 5.43B 5.31B 230B
Net income 1.35B 201M 172M 161M 147M 277M 19.2B 280M 1.9B 740M 9.64B 753M 737M 31.9B 1.75B 260M 223M 209M 191M 360M 24.94B 364M 2.47B 961M 12.52B 978M 957M 41.44B
Net Debt -4.39B -652M -559M -523M -478M -902M -62.48B -912M -6.19B -2.41B -31.37B -2.45B -2.4B -104B -3.78B -563M -482M -451M -412M -778M -53.86B -786M -5.34B -2.08B -27.05B -2.11B -2.07B -89.49B
Logo Asymchem Laboratories (Tianjin) Co., Ltd.
Asymchem Laboratories Tianjin Co Ltd is a China-based company mainly engaged in providing one-stop comprehensive services for pharmaceutical outsourcing. The Company's business includes customized research and development and production of small molecule drugs (CDMO), chemical macromolecule CDMO, clinical research services, formulation CDMO, biological macromolecule CDMO, technology output and synthetic biology. The Company's product categories cover peptides, oligonucleotides, monoclonal antibodies, antibody-conjugated drugs and messenger RNA. The Company mainly conducts its business in domestic and foreign markets.
Employees
10,617
Trader
Investor
Global
Quality
ESG MSCI
-